secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2026-06-01T20:30:18+00:00
Accession:  0001213900-26-063530
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer
--------------------------------------------------------------------------------

- 24% ORR (5 partial responses) among 21 efficacy-evaluable patients with recurrent/refractory gynecologic malignancies.
- 33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors; one response >3 years.
- Median PFS of 20.5 months among 10 patients achieving clinical benefit (48% of evaluable patients).
- Safety manageable: only 1 reversible Grade 3 capillary leak syndrome at highest dose; no new safety signals.
- Phase 2 expansion study planned to further evaluate combination in gynecologic cancers including less heavily pre-treated patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/0001213900-26-063530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea0292903-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-063530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer